

Regd. Office :-
330, TRIVIA Complex, Natubhai Circle,
Racecourse, Vadodara – 390007, Gujarat, INDIA
Phone : +91 265 2988903 / 2984803
Website : www.chemcrux.com
Email : girishshah@chemcrux.com



To
BSE LIMITED
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

04th August 2026

Dear Sir/Madam

Subject: Unaudited Financial Results for the quarter ended 30th June 2026

Ref: BSE Scrip ID: CHEMCRUX

BSE Scrip Code: 540395

We would like to inform that the Board of Directors in its meeting held today i.e., 04th August 2026 inter alia, considered and approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June 2026 as recommended by the Audit Committee.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June 2026.

Kindly take above as compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 05.00 P.M. and concluded at 07:20 P.M.

Thanking you

For CHEMCRUX ENTERPRISES LIMITED

Dipika Rajpal
Company Secretary & Compliance Officer

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,
The Board of Directors,
Chemcrux Enterprises Limited,


We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Chemcrux Enterprises Limited** ("The Company") for the **quarter ended 30th June 2026**, read together with the Notes thereon ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, together with the Notes thereon and read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Naresh & Co.
Chartered Accountants
FRN: 106928W


CA Harin Parikh
Partner
M.No. 107606
UDIN: 26107606GHADWZ3670
Place: Vadodara
Date: 04th August, 2026



CHEMCRIX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

UNAUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2026

(All amounts are in INR lacs, unless otherwise stated)

	Particulars	Quarter Ended			Year ended
		30-06-2026 Unaudited	31-03-2026 Audited	30-06-2025 Unaudited	31-03-2026 Audited
I.	Revenue from operations	2,193.81	2,428.14	1,674.74	8,257.92
II.	Other income	30.93	52.78	60.70	267.33
III.	Total Income (I+II)	2,224.73	2,480.92	1,735.44	8,525.25
IV.	Expenses:				
	Cost of materials consumed	827.51	896.67	552.72	3,264.65
	Purchase of Traded Goods				
	Changes in inventories of finished goods, by-products and work in progress	168.39	25.53	325.80	421.50
	Employee benefits expense	259.05	248.37	201.99	907.64
	Finance costs	34.31	40.48	52.41	190.53
	Depreciation and amortization expense	95.27	94.49	94.66	380.75
	Other expenses	655.12	894.64	434.79	2,639.28
	Total expenses (IV)	2,039.65	2,200.19	1,662.38	7,804.36
V.	Profit Before Tax	185.08	280.73	73.06	720.89
VIII.	Tax expense :				
	Current tax	33.00	62.88	1.42	122.00
	Deferred tax	14.65	19.17	13.19	57.23
	Income tax relating to earlier years	-	-	-	(3.30)
		47.65	82.05	14.61	175.92
IX.	Profit for the period	137.43	198.68	58.45	544.97
X	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
	- Defined Benefit Plan	(2.56)	9.68	(13.06)	(1.56)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.64)	2.44	(3.29)	(0.39)
	(iii) Items that will be reclassified to profit or loss				
	-Fair Value Gain on Investments	31.67	19.62	40.21	110.14
	(iv) Income tax relating to items that will be reclassified to profit or loss	7.97	4.94	10.12	27.72
	Total other comprehensive income, net of tax	21.79	21.93	20.32	81.25
XI.	Total comprehensive income for the period	159.22	220.61	78.76	626.22
	Paid Up Equity Share Capital (face value of Rs. 10/- each)				1,480.88
	Other Equity				6,525.82
XII.	Earnings per equity share (Nominal value per share Rs. 10/-)				
	- Basic (Rs.)	0.93	1.34	0.39	3.68
	- Diluted (Rs.)	0.93	1.34	0.39	3.68



Notes to Standalone Financial Results :

- 1 The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 2 The above financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 04th August, 2026.
- 3 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of Ind AS 108, on Operating Segment, constitute a single operating segment.
- 4 On 15th May 2026, the Company granted 1,07,700 Employee Stock Options to eligible employees under the Chemcrux Enterprises Employee Stock Option Scheme 2025 (ESOP 2025 Scheme) at an exercise price of Rs. 10 per share with a vesting period of one year. In accordance with Ind AS 102, Share-Based Payment, the Company has estimated the fair value of these options on the grant date. Consequently, the proportionate employee benefit expense attributable to this grant has been recognized in the Statement of Profit and Loss for the quarter ended June 30, 2026.
- 5 The Government of India implemented the New Labour Codes effective 21 November 2025. The Company's employee benefit structures, including gratuity, were largely in line with the new regulatory framework but still were aligned to the same as on 31st March, 2026 itself. The employee benefit expenses for the quarter ended 30 June 2026 have been accounted for accordingly. As such, the implementation did not have a material impact on the standalone financial results.
- 6 The Diluted EPS has been calculated considering the effect of Employee Stock Options in terms of Ind AS 33 Earnings Per Shares. Since there is no material effect, the Diluted EPS is appearing same as Basic EPS upon rounding off to two decimals.
- 6 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

For & on behalf of the Board
Chemcrux Enterprises Limited


Girishkumar Shah
Whole Time Director
DIN : 00469291

Place : Vadodara
Date : 04th August, 2026



INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED FINANCIAL RESULTS

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Chemcrux Enterprises Limited** ("the Holding Company") and its Subsidiary ("Kalichem Private Limited") (the Holding Company and its Subsidiary together referred to as "the Group") for the **quarter ended 30th June 2026**, read together with the Notes thereon ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") as amended.

This Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable

The Statement includes the results of M/s. Kalichem Private Limited (Subsidiary)



Based on our review conducted and procedures performed as stated above, including the limited review of the unaudited financial results of the subsidiary company performed by us, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Naresh & Co
Chartered Accountants
FRN: 106928W



CA Harin Parikh
Partner

M.No. 107606

UDIN: 26107606CDWCBG7178

Place: Vadodara

Date: 04th August, 2026



CHEMCRIX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(All amounts are in INR Lacs, Unless otherwise stated)

	Particulars	Quarter Ended			Year ended
		30-06-2026 Unaudited	31-03-2026 Audited	30-06-2025 Unaudited	31-03-2026 Audited
I.	Revenue from operations	2,193.82	2,428.20	1,650.35	8,064.64
II.	Other income	10.54	35.69	44.07	202.49
III.	Total Income (I+II)	2,204.37	2,463.88	1,694.43	8,267.13
IV.	Expenses:				
	Cost of materials consumed	833.52	898.09	472.02	2,832.61
	Purchase of Traded Goods				
	Changes in inventories of finished goods, by-products and work in progress	168.39	25.53	325.80	421.50
	Employee benefits expense	269.92	263.00	213.11	963.12
	Finance costs	63.60	70.13	85.81	314.68
	Depreciation and amortization expense	118.42	117.37	117.69	473.31
	Other expenses	652.35	822.77	476.90	2,733.69
V.	Total expenses (IV)	2,106.19	2,196.88	1,691.33	7,738.91
VI.	Profit Before Tax	98.17	267.00	3.09	528.22
VII.	Tax expense :				
	Current tax	33.00	62.88	1.42	122.00
	Deferred tax	14.65	19.17	(7.59)	36.44
	Income tax relating to earlier years		-	-	(3.30)
		47.65	82.05	(6.17)	155.14
VIII.	Profit for the period	50.52	184.95	9.27	373.08
IX.	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
	- Defined Benefit Plan	(2.56)	9.68	(13.06)	(1.56)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.64)	2.44	(3.29)	(0.39)
	(iii) Items that will be reclassified to profit or loss				
	-Fair Value Gain on Investments	31.67	19.62	40.21	110.14
	(iv) Income tax relating to items that will be reclassified to profit or loss	7.97	4.94	10.12	27.72
	Total other comprehensive income, net of tax	21.79	21.93	20.32	81.25
X.	Total comprehensive income for the period	72.31	206.88	29.58	454.33
	Profit for the period/year attributable to:				
	Owners of the Company	50.52	184.95	9.27	373.08
	Other comprehensive income for the period/year attributable to:				
	Owners of the Company	21.79	21.93	20.32	81.25
	Total comprehensive income for the period attributable to:				
	Owners of the Company	72.31	206.88	29.58	454.33
	Paid Up Equity Share Capital (face value of Rs. 10/- each)				1,480.88
	Other Equity				6,205.01
XII.	Earnings per equity share (Nominal value per share Rs. 10/-)				
	- Basic (Rs.)	0.34	1.25	0.06	2.52
	- Diluted (Rs.)	0.34	1.25	0.06	2.52



Notes to Consolidated Financial Results :

- 1 List of Entities Consolidated included in the
Kalichem Private Limited
Wholly-Owned Subsidiary
- 2 The above consolidated financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 3 The above consolidated financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 04th August, 2026
- 4 The Holding Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of Ind AS 108, on Operating Segment, constitute a single operating segment.
- 5 On 15th May 2026, the Holding Company granted 1,07,700 Employee Stock Options to eligible employees under the Chemcrux Enterprises Employee Stock Option Scheme 2025 (ESOP 2025 Scheme) at an exercise price of Rs. 10 per share with a vesting period of one year. In accordance with Ind AS 102, Share-Based Payment, the Holding Company has estimated the fair value of these options on the grant date. Consequently, the proportionate employee benefit expense attributable to this grant has been recognized in the Statement of Profit and Loss for the quarter ended June 30, 2026.
- 6 The Government of India implemented the New Labour Codes effective 21 November 2025. The Company's employee benefit structures, including gratuity, were largely in line with the new regulatory framework but still were aligned to the same as on 31st March, 2026 itself. The employee benefit expenses for the quarter ended 30 June 2026 have been accounted for accordingly. As such, the implementation did not have a material impact on the standalone financial results.
- 7 The Diluted EPS has been calculated considering the effect of Employee Stock Options in terms of Ind AS 33 Earnings Per Shares. Since there is no material effect, the Diluted EPS is appearing same as Basic EPS upon rounding off to two decimals.
- 8 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

For & on behalf of the Board
Chemcrux Enterprises Limited


Girishkumar Shah
Whole Time Director
DIN : 00469291



Place : Vadodara
Date : 04th August, 2026